Key result
This narrative review discusses the rationale, barriers, and future efforts for personalized therapy in hypertension.
Why the study?
What is the rationale, barriers, and future of personalized therapy in hypertension?
What is the rationale, barriers, and future of personalized therapy in hypertension?
This narrative review highlights the potential utility and current barriers of personalized medicine approaches in the management of hypertension.
Answers are grounded in this paper and cite their sources.
Personalized hypertension therapy lacks guideline diagnostics; leaves open prospective validation of proposed methods before clinical adoption.
In the US, hypertension affects one in three adults. Current guideline-based treatment of hypertension involves little diagnostic testing. A more personalized approach to the treatment of hypertension might be of use. Several methods of personalized treatment have been proposed and vetted to varying degrees. The purpose of this narrative review is to discuss the rationale for personalized therapy in hypertension, barriers to its development and implementation, some influential examples of proposed personalization measures, and a view of future efforts.
No takes yet. Share an insight, caveat, or question.
James Brian Byrd (2016) conducted a review in Hypertension. Personalized medicine was evaluated. This narrative review discusses the rationale, barriers, and future efforts for personalized therapy in hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: